[2] Lobaplatin is administered intravenously by bolus injection or infusion and composed of an approximate 50/50 mixture of two diastereoisomers, R,R,S- and S,S,S-configurations.

The results of current mechanistic studies suggest that lobaplatin is a DNA cross linking antineoplastic agent and has a similar platinum-induced cytotoxicity mechanism to other platin metallodrugs (i.e., cisplatin and oxaliplatin).

[3] Due to the good stability of the lactic acid leaving group, lobaplatin is more stable and therefore less toxic than first and second generation platinum-based drugs.

[2] Common side effects include agranulocytosis, thrombocytopenia, anaemia, leukopenia, nausea and vomiting.

[8] In 2003, Zentaris AG signed a contract with Hainan Tianwang International Pharmaceutical for the manufacturing and marketing of lobaplatin in China.